Skip to content
Fican Mid logo
FICAN Mid

Tays Cancer Centre and FICAN Mid

Publications

G Steven Bova – PELICAN Personalized Cancer Medicine
2020-2025

  1. Gheybi, K, Soh, PXY, Jiang, J, Mbeki, TMN, Louw, M, Burns, D et al.. Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry. Nat Commun. 2025;16 (1):8799. doi: 10.1038/s41467-025-63865-6. PubMed PMID:41038821 PubMed Central PMC12491615.
  2. Sattari, M, Rauhala, H, Latonen, L, Isaacs, WB, Nykter, M, Bova, GS et al.. Identification of protein-coding genes associated with metastatic prostate cancer. Endocr Relat Cancer. 2025;32 (7):. doi: 10.1530/ERC-25-0070. PubMed PMID:40525903 PubMed Central PMC12203752.
  3. Esentürk, E, Sahli, A, Haberland, V, Ziuboniewicz, A, Wirth, C, Bova, GS et al.. Causes of evolutionary divergence in prostate cancer. ArXiv. 2025; :. . PubMed PMID:40166741 PubMed Central PMC11957227.

Search PubMed

  1. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
  2. Woodcock, DJ, Sahli, A, Teslo, R, Bhandari, V, Gruber, AJ, Ziubroniewicz, A et al.. Genomic evolution shapes prostate cancer disease type. Cell Genom. 2024;4 (3):100511. doi: 10.1016/j.xgen.2024.100511. PubMed PMID:38428419 PubMed Central PMC10943594.

Search PubMed

  1. Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Takala, E, Paakinaho, V, Nykter, M et al.. Fanconi anemia pathway regulation by FANCI in prostate cancer. Front Oncol. 2023;13 :1260826. doi: 10.3389/fonc.2023.1260826. PubMed PMID:38023254 PubMed Central PMC10643534.
  2. Nurminen, A, Jaatinen, S, Taavitsainen, S, Högnäs, G, Lesluyes, T, Ansari-Pour, N et al.. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Genome Med. 2023;15 (1):82. doi: 10.1186/s13073-023-01242-y. PubMed PMID:37828555 PubMed Central PMC10571458.
  3. Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
  4. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2023;41 (4):577. doi: 10.1038/s41587-022-01554-1. PubMed PMID:36944844 PubMed Central PMC10110458.
  5. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2023;55 (6):1080. doi: 10.1038/s41588-023-01319-9. PubMed PMID:36944736 PubMed Central PMC10260396.
  6. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2023;55 (6):1079. doi: 10.1038/s41588-023-01318-w. PubMed PMID:36944735 PubMed Central PMC10260394.
  7. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. Author Correction: The landscape of viral associations in human cancers. Nat Genet. 2023;55 (6):1077. doi: 10.1038/s41588-023-01316-y. PubMed PMID:36944734 PubMed Central PMC10260395.
  8. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2023;55 (6):1076. doi: 10.1038/s41588-023-01315-z. PubMed PMID:36944733 PubMed Central PMC10260391.
  9. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2023;55 (6):1078. doi: 10.1038/s41588-023-01317-x. PubMed PMID:36944732 PubMed Central PMC10260393.
  10. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. Author Correction: The repertoire of mutational signatures in human cancer. Nature. 2023;614 (7948):E41. doi: 10.1038/s41586-022-05600-5. PubMed PMID:36697836 PubMed Central PMC9931578.
  11. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023;614 (7948):E38. doi: 10.1038/s41586-022-05597-x. PubMed PMID:36697835 PubMed Central PMC9931568.
  12. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. Nature. 2023;614 (7948):E39. doi: 10.1038/s41586-022-05598-w. PubMed PMID:36697834 PubMed Central PMC9931570.
  13. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023;614 (7948):E42. doi: 10.1038/s41586-022-05601-4. PubMed PMID:36697833 PubMed Central PMC9931577.
  14. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023;614 (7948):E40. doi: 10.1038/s41586-022-05599-9. PubMed PMID:36697832 PubMed Central PMC9931557.
  15. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Author Correction: Genomic basis for RNA alterations in cancer. Nature. 2023;614 (7948):E37. doi: 10.1038/s41586-022-05596-y. PubMed PMID:36697831 PubMed Central PMC9931574.

Search PubMed

  1. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2022;5 (1):1347. doi: 10.1038/s42003-022-03769-z. PubMed PMID:36482178 PubMed Central PMC9732278.
  2. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2022;13 (1):7567. doi: 10.1038/s41467-022-32336-7. PubMed PMID:36482170 PubMed Central PMC9731941.
  3. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2022;13 (1):7574. doi: 10.1038/s41467-022-32328-7. PubMed PMID:36481818 PubMed Central PMC9731961.
  4. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2022;13 (1):7571. doi: 10.1038/s41467-022-32343-8. PubMed PMID:36481739 PubMed Central PMC9732291.
  5. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Author Correction: Inferring structural variant cancer cell fraction. Nat Commun. 2022;13 (1):7568. doi: 10.1038/s41467-022-32338-5. PubMed PMID:36481724 PubMed Central PMC9732297.
  6. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2022;13 (1):7573. doi: 10.1038/s41467-022-32329-6. PubMed PMID:36481665 PubMed Central PMC9732335.
  7. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Author Correction: Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2022;13 (1):7570. doi: 10.1038/s41467-022-32342-9. PubMed PMID:36481658 PubMed Central PMC9731958.
  8. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2022;13 (1):7572. doi: 10.1038/s41467-022-32333-w. PubMed PMID:36481652 PubMed Central PMC9732340.
  9. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2022;13 (1):7569. doi: 10.1038/s41467-022-32339-4. PubMed PMID:36481612 PubMed Central PMC9731962.
  10. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2022;13 (1):7566. doi: 10.1038/s41467-022-32334-9. PubMed PMID:36481610 PubMed Central PMC9732045.
  11. Buhigas, C, Warren, AY, Leung, WK, Whitaker, HC, Luxton, HJ, Hawkins, S et al.. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022;21 (1):183. doi: 10.1186/s12943-022-01644-3. PubMed PMID:36131292 PubMed Central PMC9494848.
  12. Ouellet, V, Erickson, A, GAP1 UTMAs Contributing Investigators, Wiley, K, Morrissey, C, Berge, V et al.. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiol Biomarkers Prev. 2022;31 (4):715-727. doi: 10.1158/1055-9965.EPI-21-0600. PubMed PMID:35131885 PubMed Central PMC9381093.

Search PubMed

  1. Li, QK, Chen, J, Hu, Y, Höti, N, Lih, TM, Thomas, SN et al.. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Sci Rep. 2021;11 (1):18936. doi: 10.1038/s41598-021-98410-0. PubMed PMID:34556748 PubMed Central PMC8460832.
  2. Ketola, K, Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Järvelä, E, Rodríguez-Martín, B et al.. Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Res. 2021;81 (19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. PubMed PMID:34348967 PubMed Central PMC9397610.
  3. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
  4. Valkonen, M, Hognas, G, Bova, GS, Ruusuvuori, P. Generalized Fixation Invariant Nuclei Detection Through Domain Adaptation Based Deep Learning. IEEE J Biomed Health Inform. 2021;25 (5):1747-1757. doi: 10.1109/JBHI.2020.3039414. PubMed PMID:33211668 .

Search PubMed

  1. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
  2. Woodcock, DJ, Riabchenko, E, Taavitsainen, S, Kankainen, M, Gundem, G, Brewer, DS et al.. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11 (1):5070. doi: 10.1038/s41467-020-18843-5. PubMed PMID:33033260 PubMed Central PMC7545111.
  3. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
  4. Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
  5. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. 2020;584 (7820):E18. doi: 10.1038/s41586-020-2581-5. PubMed PMID:32728210 .
  6. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Genomic basis for RNA alterations in cancer. Nature. 2020;578 (7793):129-136. doi: 10.1038/s41586-020-1970-0. PubMed PMID:32025019 PubMed Central PMC7054216.
  7. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. The repertoire of mutational signatures in human cancer. Nature. 2020;578 (7793):94-101. doi: 10.1038/s41586-020-1943-3. PubMed PMID:32025018 PubMed Central PMC7054213.
  8. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578 (7793):102-111. doi: 10.1038/s41586-020-1965-x. PubMed PMID:32025015 PubMed Central PMC7054214.
  9. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. The evolutionary history of 2,658 cancers. Nature. 2020;578 (7793):122-128. doi: 10.1038/s41586-019-1907-7. PubMed PMID:32025013 PubMed Central PMC7054212.
  10. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578 (7793):112-121. doi: 10.1038/s41586-019-1913-9. PubMed PMID:32025012 PubMed Central PMC7025897.
  11. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578 (7793):82-93. doi: 10.1038/s41586-020-1969-6. PubMed PMID:32025007 PubMed Central PMC7025898.
  12. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52 (3):331-341. doi: 10.1038/s41588-019-0576-7. PubMed PMID:32025003 PubMed Central PMC7058534.
  13. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. The landscape of viral associations in human cancers. Nat Genet. 2020;52 (3):320-330. doi: 10.1038/s41588-019-0558-9. PubMed PMID:32025001 PubMed Central PMC8076016.
  14. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52 (3):294-305. doi: 10.1038/s41588-019-0564-y. PubMed PMID:32024999 PubMed Central PMC7058537.
  15. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52 (3):306-319. doi: 10.1038/s41588-019-0562-0. PubMed PMID:32024998 PubMed Central PMC7058536.
  16. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52 (3):342-352. doi: 10.1038/s41588-019-0557-x. PubMed PMID:32024997 PubMed Central PMC7058535.
  17. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2020;3 (1):56. doi: 10.1038/s42003-019-0741-7. PubMed PMID:32024996 PubMed Central PMC7002399.
  18. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2020;38 (3):288-292. doi: 10.1038/s41587-019-0360-3. PubMed PMID:32024987 PubMed Central PMC7062635.
  19. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2020;11 (1):729. doi: 10.1038/s41467-020-14367-0. PubMed PMID:32024854 PubMed Central PMC7002574.
  20. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11 (1):728. doi: 10.1038/s41467-019-13825-8. PubMed PMID:32024849 PubMed Central PMC7002586.
  21. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11 (1):735. doi: 10.1038/s41467-019-13983-9. PubMed PMID:32024846 PubMed Central PMC7002665.
  22. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Inferring structural variant cancer cell fraction. Nat Commun. 2020;11 (1):730. doi: 10.1038/s41467-020-14351-8. PubMed PMID:32024845 PubMed Central PMC7002525.
  23. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2020;11 (1):731. doi: 10.1038/s41467-020-14352-7. PubMed PMID:32024834 PubMed Central PMC7002414.
  24. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2020;11 (1):736. doi: 10.1038/s41467-019-13885-w. PubMed PMID:32024823 PubMed Central PMC7002524.
  25. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11 (1):737. doi: 10.1038/s41467-019-14052-x. PubMed PMID:32024819 PubMed Central PMC7002770.
  26. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11 (1):734. doi: 10.1038/s41467-019-13929-1. PubMed PMID:32024818 PubMed Central PMC7002750.
  27. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11 (1):733. doi: 10.1038/s41467-019-13824-9. PubMed PMID:32024817 PubMed Central PMC7002710.

Search PubMed

Search PubMed

Jorma Isola – Cancer biology
2021-2025

Search PubMed

  1. Daveson, AJM, Stubbs, R, Polasek, TM, Isola, J, Anderson, R, Tye-Din, JA et al.. Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2025;10 (1):44-54. doi: 10.1016/S2468-1253(24)00248-6. PubMed PMID:39521016 .
  2. Dotsenko, V, Tewes, B, Hils, M, Pasternack, R, Isola, J, Taavela, J et al.. Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nat Immunol. 2024;25 (7):1218-1230. doi: 10.1038/s41590-024-01867-0. PubMed PMID:38914866 PubMed Central PMC11224021.

Search PubMed

Search PubMed

  1. Murray, JA, Syage, JA, Wu, TT, Dickason, MA, Ramos, AG, Van Dyke, C et al.. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022;163 (6):1510-1521.e6. doi: 10.1053/j.gastro.2022.07.071. PubMed PMID:35931103 PubMed Central PMC9707643.
  2. Närvä, E, Taskinen, ME, Lilla, S, Isomursu, A, Pietilä, M, Weltner, J et al.. MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. iScience. 2022;25 (6):104459. doi: 10.1016/j.isci.2022.104459. PubMed PMID:35677646 PubMed Central PMC9167974.
  3. Puttonen, M, Isola, J, Ylinen, O, Böhling, T, Koljonen, V, Sihto, H et al.. UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. Sci Rep. 2022;12 (1):5529. doi: 10.1038/s41598-022-09490-5. PubMed PMID:35365704 PubMed Central PMC8976087.
  4. Bychkov, D, Joensuu, H, Nordling, S, Tiulpin, A, Kücükel, H, Lundin, M et al.. Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series. J Pathol Inform. 2022;13 :9. doi: 10.4103/jpi.jpi_29_21. PubMed PMID:35136676 PubMed Central PMC8794033.
  5. Andriulli, A, Bevilacqua, A, Palmieri, O, Latiano, A, Fontana, R, Gioffreda, D et al.. Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control study. Food Funct. 2022;13 (3):1299-1315. doi: 10.1039/d1fo00490e. PubMed PMID:35029612 .

Search PubMed

Search PubMed

Pirkko Kellokumpu-Lehtinen – Radiotherapy and Oncology
2018-2025

Search PubMed

Search PubMed

Search PubMed

  1. Gillessen, S, Bossi, A, Davis, ID, de Bono, J, Fizazi, K, James, ND et al.. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83 (3):267-293. doi: 10.1016/j.eururo.2022.11.002. PubMed PMID:36494221 PubMed Central PMC7614721.
  2. Reinikainen, P, Lehtonen, M, Lehtinen, I, Luukkaala, T, Sintonen, H, Kellokumpu-Lehtinen, PL et al.. Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population. Clin Genitourin Cancer. 2023;21 (1):146-154. doi: 10.1016/j.clgc.2022.07.013. PubMed PMID:36038484 .
  3. Kokkonen, K, Kellokumpu-Lehtinen, PL, Kankaanpää, M, Nikander, R, Penttinen, HM, Utriainen, M et al.. Factors predicting long-term physical activity of breast cancer survivors. 5-year-follow-up of the BREX exercise intervention study. Acta Oncol. 2022;61 (10):1200-1208. doi: 10.1080/0284186X.2022.2103388. PubMed PMID:35881067 .
  4. Lehtonen, M, Sormunen, J, Luukkaala, T, Marttila, T, McDermott, R, Joensuu, T et al.. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. Acta Oncol. 2022;61 (8):963-971. doi: 10.1080/0284186X.2022.2098680. PubMed PMID:35847998 .
  5. Tuohinen, SS, Aula, H, Skyttä, T, Huhtala, H, Keski-Pukkila, K, Nikus, K et al.. A Higher Mean Heart Radiation Dose Induces Higher Frequency of Multiple Cardiac Changes. Anticancer Res. 2022;42 (5):2519-2529. doi: 10.21873/anticanres.15730. PubMed PMID:35489742 .
  6. Tuohinen, SS, Skytta, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL, Raatikainen, P et al.. Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis – A Prospective Three-year Study. Anticancer Res. 2022;42 (5):2507-2517. doi: 10.21873/anticanres.15729. PubMed PMID:35489739 .
  7. Reinikainen, P, Kapanen, M, Luukkaala, T, Kellokumpu-Lehtinen, PL. Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer. Anticancer Res. 2022;42 (5):2553-2565. doi: 10.21873/anticanres.15733. PubMed PMID:35489724 .
  8. Lehtomäki, K, Stedt, HP, Osterlund, E, Muhonen, T, Soveri, LM, Halonen, P et al.. Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers (Basel). 2022;14 (7):. doi: 10.3390/cancers14071713. PubMed PMID:35406485 PubMed Central PMC8996978.
  9. Bychkov, D, Joensuu, H, Nordling, S, Tiulpin, A, Kücükel, H, Lundin, M et al.. Outcome and Biomarker Supervised Deep Learning for Survival Prediction in Two Multicenter Breast Cancer Series. J Pathol Inform. 2022;13 :9. doi: 10.4103/jpi.jpi_29_21. PubMed PMID:35136676 PubMed Central PMC8794033.
  10. Poikonen-Saksela, P, Kolokotroni, E, Vehmanen, L, Mattson, J, Stamatakos, G, Huovinen, R et al.. A graphical LASSO analysis of global quality of life, sub scales of the EORTC QLQ-C30 instrument and depression in early breast cancer. Sci Rep. 2022;12 (1):2112. doi: 10.1038/s41598-022-06138-2. PubMed PMID:35136160 PubMed Central PMC8826362.
  11. Joensuu, H, Kellokumpu-Lehtinen, PL, Huovinen, R, Jukkola, A, Tanner, M, Ahlgren, J et al.. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022;40 (10):1051-1058. doi: 10.1200/JCO.21.02054. PubMed PMID:35020465 PubMed Central PMC8966968.
  12. Loi, S, Salgado, R, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M et al.. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022;8 (1):3. doi: 10.1038/s41523-021-00362-1. PubMed PMID:35017545 PubMed Central PMC8752727.
  13. Lehtonen, M, Sormunen, J, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Huttunen, T, Ginman, C et al.. Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study. Anticancer Res. 2022;42 (1):87-92. doi: 10.21873/anticanres.15460. PubMed PMID:34969712 .
  14. Bärlund, M, Takala, L, Tianen, L, Kellokumpu-Lehtinen, PL. Real-world Evidence of Implementing eHealth Enables Fluent Symptom-based Follow-up of a Growing Number of Patients with Breast Cancer with the Same Healthcare Resources. Clin Breast Cancer. 2022;22 (3):261-268. doi: 10.1016/j.clbc.2021.09.005. PubMed PMID:34657816 .

Search PubMed

Search PubMed

Search PubMed

Search PubMed

  1. Lehto, US, Ojanen, M, Väkevä, A, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P et al.. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer. Qual Life Res. 2019;28 (3):677-686. doi: 10.1007/s11136-018-2069-z. PubMed PMID:30511254 PubMed Central PMC6394517.
  2. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer. Radiat Oncol. 2018;13 (1):201. doi: 10.1186/s13014-018-1150-7. PubMed PMID:30340644 PubMed Central PMC6194684.
  3. Wu, X, Reinikainen, P, Kapanen, M, Vierikko, T, Ryymin, P, Kellokumpu-Lehtinen, PL et al.. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. Contrast Media Mol Imaging. 2018;2018 :3181258. doi: 10.1155/2018/3181258. PubMed PMID:30327584 PubMed Central PMC6169212.
  4. Leivonen, SK, Pollari, M, Brück, O, Pellinen, T, Autio, M, Karjalainen-Lindsberg, ML et al.. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104 (2):338-346. doi: 10.3324/haematol.2018.200105. PubMed PMID:30237271 PubMed Central PMC6355505.
  5. Kaikkonen, E, Rantapero, T, Zhang, Q, Taimen, P, Laitinen, V, Kallajoki, M et al.. ANO7 is associated with aggressive prostate cancer. Int J Cancer. 2018;143 (10):2479-2487. doi: 10.1002/ijc.31746. PubMed PMID:30157291 PubMed Central PMC6589920.
  6. Pollari, M, Brück, O, Pellinen, T, Vähämurto, P, Karjalainen-Lindsberg, ML, Mannisto, S et al.. PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018;103 (11):1908-1914. doi: 10.3324/haematol.2018.197194. PubMed PMID:30026337 PubMed Central PMC6278972.
  7. Piili, RP, Lehto, JT, Luukkaala, T, Hinkka, H, Kellokumpu-Lehtinen, PI. Does special education in palliative medicine make a difference in end-of-life decision-making?. BMC Palliat Care. 2018;17 (1):94. doi: 10.1186/s12904-018-0349-6. PubMed PMID:30021586 PubMed Central PMC6052558.
  8. Joensuu, H, Fraser, J, Wildiers, H, Huovinen, R, Auvinen, P, Utriainen, M et al.. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA Oncol. 2018;4 (9):1199-1206. doi: 10.1001/jamaoncol.2018.1380. PubMed PMID:29852043 PubMed Central PMC6143012.
  9. Piili, RP, Metsänoja, R, Hinkka, H, Kellokumpu-Lehtinen, PI, Lehto, JT. Changes in attitudes towards hastened death among Finnish physicians over the past sixteen years. BMC Med Ethics. 2018;19 (1):40. doi: 10.1186/s12910-018-0290-5. PubMed PMID:29843682 PubMed Central PMC5975714.
  10. Tuohinen, SS, Keski-Pukkila, K, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer. Anticancer Res. 2018;38 (4):2207-2215. doi: 10.21873/anticanres.12463. PubMed PMID:29599341 .
  11. Motzer, RJ, Tannir, NM, McDermott, DF, Arén Frontera, O, Melichar, B, Choueiri, TK et al.. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378 (14):1277-1290. doi: 10.1056/NEJMoa1712126. PubMed PMID:29562145 PubMed Central PMC5972549.
  12. Sperinde, J, Huang, W, Vehtari, A, Chenna, A, Kellokumpu-Lehtinen, PL, Winslow, J et al.. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clin Cancer Res. 2018;24 (13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. PubMed PMID:29535130 .
  13. Schmidt, M, Weyer-Elberich, V, Hengstler, JG, Heimes, AS, Almstedt, K, Gerhold-Ay, A et al.. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20 (1):15. doi: 10.1186/s13058-018-0942-x. PubMed PMID:29482642 PubMed Central PMC5827982.
  14. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
  15. Hietanen, T, Kapanen, M, Kellokumpu-Lehtinen, PL. Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines. Anticancer Res. 2018;38 (2):655-663. doi: 10.21873/anticanres.12269. PubMed PMID:29374687 .
  16. Tuohinen, SS, Rankinen, J, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Associations between ECG changes and echocardiographic findings in patients with acute non-ST elevation myocardial infarction. J Electrocardiol. 2018;51 (2):188-194. doi: 10.1016/j.jelectrocard.2017.11.007. PubMed PMID:29174705 .
  17. Pajamäki, N, Metso, S, Hakala, T, Ebeling, T, Huhtala, H, Ryödi, E et al.. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018;88 (2):303-310. doi: 10.1111/cen.13519. PubMed PMID:29154445 .
  18. Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bossi, A, Bristow, R et al.. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73 (2):178-211. doi: 10.1016/j.eururo.2017.06.002. PubMed PMID:28655541 .

Search PubMed

Olli Lohi – Hematology and oncology
2020-2025

Search PubMed

Search PubMed

Search PubMed

  1. Peterziel, H, Jamaladdin, N, ElHarouni, D, Gerloff, XF, Herter, S, Fiesel, P et al.. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ Precis Oncol. 2022;6 (1):94. doi: 10.1038/s41698-022-00335-y. PubMed PMID:36575299 PubMed Central PMC9794727.
  2. Pilheden, M, Ahlgren, L, Hyrenius-Wittsten, A, Gonzalez-Pena, V, Sturesson, H, Hansen Marquart, HV et al.. Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood -rearranged Acute Leukemia. Hemasphere. 2022;6 (10):e785. doi: 10.1097/HS9.0000000000000785. PubMed PMID:36204688 PubMed Central PMC9529062.
  3. Andersson, NG, Rathe, M, Mølle, I, Jarvis, KB, Hoffmann, M, Huurre, A et al.. A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management. Br J Haematol. 2022;199 (1):117-121. doi: 10.1111/bjh.18397. PubMed PMID:35922061 PubMed Central PMC9804349.
  4. Abuhamed, J, Nikkilä, A, Raitanen, J, Alimam, W, Lohi, O, Pitkäniemi, J et al.. Incidence trends of childhood central nervous system tumors in Finland 1990-2017. BMC Cancer. 2022;22 (1):784. doi: 10.1186/s12885-022-09862-0. PubMed PMID:35850678 PubMed Central PMC9290294.
  5. Vuorenoja, S, Vettenranta, K, Lohi, O. Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection. Cancer Rep (Hoboken). 2022;5 (10):e1663. doi: 10.1002/cnr2.1663. PubMed PMID:35796282 PubMed Central PMC9575499.
  6. Nikkilä, A, Lohi, O, Nieminen, N, Csonka, P. Trends in ferritin measurements in children and adolescents: A Finnish 9-year observational study. Acta Paediatr. 2022;111 (10):1933-1940. doi: 10.1111/apa.16454. PubMed PMID:35708115 PubMed Central PMC9541652.
  7. Schober, SJ, Hallmen, E, Reßle, F, Gassmann, H, Prexler, C, Wawer, A et al.. No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy. Front Oncol. 2022;12 :878367. doi: 10.3389/fonc.2022.878367. PubMed PMID:35619911 PubMed Central PMC9127413.
  8. Oksa, L, Mäkinen, A, Nikkilä, A, Hyvärinen, N, Laukkanen, S, Rokka, A et al.. Arginine Methyltransferase PRMT7 Deregulates Expression of RUNX1 Target Genes in T-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2022;14 (9):. doi: 10.3390/cancers14092169. PubMed PMID:35565298 PubMed Central PMC9101393.
  9. Laukkanen, S, Veloso, A, Yan, C, Oksa, L, Alpert, EJ, Do, D et al.. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140 (17):1891-1906. doi: 10.1182/blood.2021015106. PubMed PMID:35544598 PubMed Central PMC10082361.
  10. Långström, S, Huurre, A, Kari, J, Lohi, O, Sievänen, H, Palmu, S et al.. Bioimpedance spinal needle provides high success and low complication rate in lumbar punctures of pediatric patients with acute lymphoblastic leukemia. Sci Rep. 2022;12 (1):6799. doi: 10.1038/s41598-022-10915-4. PubMed PMID:35474331 PubMed Central PMC9042945.
  11. Ventelä, J, Nikkilä, A, Jukkola, A, Lohi, O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. Acta Paediatr. 2022;111 (2):442-444. doi: 10.1111/apa.16161. PubMed PMID:34689375 PubMed Central PMC9299452.

Search PubMed

  1. Ventelä, J, Nikkilä, A, Jukkola, A, Lohi, O. Incidence and outcomes of cancer in 16- to 17-year-old adolescents. Acta Paediatr. 2022;111 (2):442-444. doi: 10.1111/apa.16161. PubMed PMID:34689375 PubMed Central PMC9299452.
  2. van Tilburg, CM, Pfaff, E, Pajtler, KW, Langenberg, KPS, Fiesel, P, Jones, BC et al.. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021;11 (11):2764-2779. doi: 10.1158/2159-8290.CD-21-0094. PubMed PMID:34373263 PubMed Central PMC9414287.
  3. Immonen, E, Nikkilä, A, Peltomäki, T, Aine, L, Lohi, O. Late adverse effects of childhood acute lymphoblastic leukemia treatment on developing dentition. Pediatr Blood Cancer. 2021;68 (9):e29200. doi: 10.1002/pbc.29200. PubMed PMID:34228397 .
  4. Mäkinen, A, Nikkilä, A, Mehtonen, J, Teppo, S, Oksa, L, Nordlund, J et al.. Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis. Pathology. 2021;53 (7):875-882. doi: 10.1016/j.pathol.2021.02.013. PubMed PMID:34049715 .
  5. Mäkinen, A, Nikkilä, A, Haapaniemi, T, Oksa, L, Mehtonen, J, Vänskä, M et al.. Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia. Cancers (Basel). 2021;13 (7):. doi: 10.3390/cancers13071505. PubMed PMID:33805930 PubMed Central PMC8037952.
  6. Winter, G, Kirschner-Schwabe, R, Groeneveld-Krentz, S, Escherich, G, Möricke, A, von Stackelberg, A et al.. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome. Leukemia. 2021;35 (5):1475-1479. doi: 10.1038/s41375-021-01163-y. PubMed PMID:33580201 PubMed Central PMC8102191.

Search PubMed

  1. Abuhamed, J, Nikkilä, A, Lohi, O, Auvinen, A. Trends of computed tomography use among children in Finland. Eur J Radiol Open. 2020;7 :100290. doi: 10.1016/j.ejro.2020.100290. PubMed PMID:33335951 PubMed Central PMC7733003.
  2. Mehtonen, J, Teppo, S, Lahnalampi, M, Kokko, A, Kaukonen, R, Oksa, L et al.. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020;12 (1):99. doi: 10.1186/s13073-020-00799-2. PubMed PMID:33218352 PubMed Central PMC7679990.
  3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
  4. Laukkanen, S, Oksa, L, Nikkilä, A, Lahnalampi, M, Parikka, M, Seki, M et al.. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome. Leuk Lymphoma. 2020;61 (13):3089-3100. doi: 10.1080/10428194.2020.1804560. PubMed PMID:32835548 .
  5. Immonen, E, Aine, L, Nikkilä, A, Parikka, M, Grönroos, M, Vepsäläinen, K et al.. Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer. Pediatr Blood Cancer. 2020;67 (10):e28520. doi: 10.1002/pbc.28520. PubMed PMID:32725875 .
  6. Chan, LN, Murakami, MA, Robinson, ME, Caeser, R, Sadras, T, Lee, J et al.. Signalling input from divergent pathways subverts B cell transformation. Nature. 2020;583 (7818):845-851. doi: 10.1038/s41586-020-2513-4. PubMed PMID:32699415 PubMed Central PMC7394729.
  7. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
  8. Karalexi, MA, Dessypris, N, Ma, X, Spector, LG, Marcotte, E, Clavel, J et al.. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130 :1-11. doi: 10.1016/j.ejca.2020.01.018. PubMed PMID:32163883 .
  9. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica. 2020;105 (3):849-850. doi: 10.3324/haematol.2019.245704. PubMed PMID:32115415 PubMed Central PMC7049358.
  10. Grönroos, T, Mäkinen, A, Laukkanen, S, Mehtonen, J, Nikkilä, A, Oksa, L et al.. Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia. Sci Rep. 2020;10 (1):2043. doi: 10.1038/s41598-020-58970-z. PubMed PMID:32029838 PubMed Central PMC7005266.
  11. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scand J Work Environ Health. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
  12. Harjula, SE, Saralahti, AK, Ojanen, MJT, Rantapero, T, Uusi-Mäkelä, MIE, Nykter, M et al.. Characterization of immune response against Mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (Danio rerio). Dev Comp Immunol. 2020;103 :103523. doi: 10.1016/j.dci.2019.103523. PubMed PMID:31626817 .
  13. Heikkilä, P, Kokko, P, Lohi, O, Korppi, M. Nursing intensity scores did not correlate well with reimbursement claims for infant bronchiolitis. Acta Paediatr. 2020;109 (1):140-146. doi: 10.1111/apa.14926. PubMed PMID:31269265 .

Search PubMed

Search PubMed

Search PubMed

Johanna Mäenpää – Gynaecological oncology
2020-2025

Search PubMed

Search PubMed

Search PubMed

Search PubMed

Search PubMed

Search PubMed

Search PubMed

  1. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .
  2. Niemi, RJ, Braicu, EI, Kulbe, H, Koistinen, KM, Sehouli, J, Puistola, U et al.. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018;119 (7):847-854. doi: 10.1038/s41416-018-0270-z. PubMed PMID:30293997 PubMed Central PMC6189177.
  3. Niemi, RJ, Roine, AN, Eräviita, E, Kumpulainen, PS, Mäenpää, JU, Oksala, N et al.. FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer. Gynecol Oncol. 2018;151 (3):519-524. doi: 10.1016/j.ygyno.2018.09.016. PubMed PMID:30257785 .
  4. Antila-Långsjö, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Cesarean scar defect: a prospective study on risk factors. Am J Obstet Gynecol. 2018;219 (5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. PubMed PMID:30240650 .
  5. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
  6. Antila-Långsjö, R, Mäenpää, JU, Huhtala, H, Tomás, E, Staff, S. Comparison of transvaginal ultrasound and saline contrast sonohysterography in evaluation of cesarean scar defect: a prospective cohort study. Acta Obstet Gynecol Scand. 2018;97 (9):1130-1136. doi: 10.1111/aogs.13367. PubMed PMID:29754409 .
  7. Mäenpää, MM, Nieminen, K, Tomás, EI, Luukkaala, TH, Mäenpää, JU. Robotic-Assisted Infrarenal Para-aortic Lymphadenectomy in Gynecological Cancers: Technique and Surgical Outcomes. Int J Gynecol Cancer. 2018;28 (5):951-958. doi: 10.1097/IGC.0000000000001249. PubMed PMID:29683877 .
  8. Palmér, R, Mäenpää, J, Jauhiainen, A, Larsson, B, Mo, J, Russell, M et al.. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects. Clin Pharmacol Ther. 2018;104 (6):1155-1164. doi: 10.1002/cpt.1053. PubMed PMID:29484635 PubMed Central PMC6282495.

Search PubMed

Daniela Ungureanu – Cancer Signalling
2020-2024

Search PubMed

Search PubMed

Search PubMed

  1. Kohtamäki, L, Arjama, M, Mäkelä, S, Ianevski, P, Välimäki, K, Juteau, S et al.. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Transl Oncol. 2022;15 (1):101290. doi: 10.1016/j.tranon.2021.101290. PubMed PMID:34837846 PubMed Central PMC8633005.
  2. Jacome Sanz, D, Raivola, J, Karvonen, H, Arjama, M, Barker, H, Murumägi, A et al.. Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers (Basel). 2021;13 (15):. doi: 10.3390/cancers13153727. PubMed PMID:34359627 PubMed Central PMC8345177.
  3. Murumägi, A, Ungureanu, D, Arjama, M, Bützow, R, Lohi, J, Sariola, H et al.. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. Transl Oncol. 2021;14 (4):101027. doi: 10.1016/j.tranon.2021.101027. PubMed PMID:33530027 PubMed Central PMC7851186.

Search PubMed

  1. Karvonen, H, Arjama, M, Kaleva, L, Niininen, W, Barker, H, Koivisto-Korander, R et al.. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11 (9):790. doi: 10.1038/s41419-020-03009-4. PubMed PMID:32989221 PubMed Central PMC7522257.
  2. Sheetz, JB, Mathea, S, Karvonen, H, Malhotra, K, Chatterjee, D, Niininen, W et al.. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Mol Cell. 2020;79 (3):390-405.e7. doi: 10.1016/j.molcel.2020.06.018. PubMed PMID:32619402 PubMed Central PMC7543951.

Search PubMed

  1. Karvonen, H, Barker, H, Kaleva, L, Niininen, W, Ungureanu, D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019;8 (8):. doi: 10.3390/cells8080812. PubMed PMID:31382410 PubMed Central PMC6721603.
  2. Tudor, Ș, Minciună, C, Lăcătuş, M, Gavrilă, D, Manciu, S, Ungureanu, D et al.. Transanal Total Mesorectal Excision – A Case Report. Chirurgia (Bucur). 2019;114 (2):278-283. doi: 10.21614/chirurgia.114.2.278. PubMed PMID:31060661 .
  3. Karvonen, H, Perttilä, R, Niininen, W, Hautanen, V, Barker, H, Murumägi, A et al.. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene. 2019;38 (17):3288-3300. doi: 10.1038/s41388-018-0670-9. PubMed PMID:30631148 .

Search PubMed

  1. Karvonen, H, Perttilä, R, Niininen, W, Barker, H, Ungureanu, D. Targeting Wnt signaling pseudokinases in hematological cancers. Eur J Haematol. 2018;101 (4):457-465. doi: 10.1111/ejh.13137. PubMed PMID:29989208 .
  2. Karvonen, H, Summala, K, Niininen, W, Barker, HR, Ungureanu, D. Interaction between ROR1 and MuSK activation complex in myogenic cells. FEBS Lett. 2018;592 (3):434-445. doi: 10.1002/1873-3468.12966. PubMed PMID:29292499 .

Search PubMed

Tapio Visakorpi – Molecular Biology of Prostate Cancer
2020-2025

Search PubMed

  1. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
  2. Lawlor, A, Beyer, K, Russell, B, Steinbeisser, C, Bjartell, A, De Meulder, B et al.. PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research. Nat Rev Urol. 2025;22 (2):116-124. doi: 10.1038/s41585-024-00925-4. PubMed PMID:39251785 .
  3. Kohvakka, A, Sattari, M, Nättinen, J, Aapola, U, Gregorová, P, Tammela, TLJ et al.. Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer. Cancer Gene Ther. 2024;31 (10):1536-1546. doi: 10.1038/s41417-024-00822-3. PubMed PMID:39147845 PubMed Central PMC11489079.
  4. Olotu, O, Koskenniemi, AR, Ma, L, Paramonov, V, Laasanen, S, Louramo, E et al.. Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth. Cell Rep. 2024;43 (7):114430. doi: 10.1016/j.celrep.2024.114430. PubMed PMID:38963760 .
  5. Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.

Search PubMed

  1. Russell, B, Beyer, K, Lawlor, A, Roobol, MJ, Venderbos, LDF, Remmers, S et al.. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?. Eur Urol Open Sci. 2024;59 :27-29. doi: 10.1016/j.euros.2023.11.004. PubMed PMID:38298764 PubMed Central PMC10829596.
  2. Nurminen, A, Jaatinen, S, Taavitsainen, S, Högnäs, G, Lesluyes, T, Ansari-Pour, N et al.. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. Genome Med. 2023;15 (1):82. doi: 10.1186/s13073-023-01242-y. PubMed PMID:37828555 PubMed Central PMC10571458.
  3. Sattari, M, Kohvakka, A, Moradi, E, Rauhala, H, Urhonen, H, Isaacs, WB et al.. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. Endocr Relat Cancer. 2023;30 (8):. doi: 10.1530/ERC-22-0247. PubMed PMID:37140987 PubMed Central PMC10326635.
  4. Omar, MI, MacLennan, S, Ribal, MJ, Roobol, MJ, Dimitropoulos, K, van den Broeck, T et al.. Unanswered questions in prostate cancer – findings of an international multi-stakeholder consensus by the PIONEER consortium. Nat Rev Urol. 2023;20 (8):494-501. doi: 10.1038/s41585-023-00748-9. PubMed PMID:37012441 .
  5. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2023;41 (4):577. doi: 10.1038/s41587-022-01554-1. PubMed PMID:36944844 PubMed Central PMC10110458.
  6. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2023;55 (6):1080. doi: 10.1038/s41588-023-01319-9. PubMed PMID:36944736 PubMed Central PMC10260396.
  7. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2023;55 (6):1079. doi: 10.1038/s41588-023-01318-w. PubMed PMID:36944735 PubMed Central PMC10260394.
  8. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. Author Correction: The landscape of viral associations in human cancers. Nat Genet. 2023;55 (6):1077. doi: 10.1038/s41588-023-01316-y. PubMed PMID:36944734 PubMed Central PMC10260395.
  9. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2023;55 (6):1076. doi: 10.1038/s41588-023-01315-z. PubMed PMID:36944733 PubMed Central PMC10260391.
  10. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2023;55 (6):1078. doi: 10.1038/s41588-023-01317-x. PubMed PMID:36944732 PubMed Central PMC10260393.
  11. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. Author Correction: The repertoire of mutational signatures in human cancer. Nature. 2023;614 (7948):E41. doi: 10.1038/s41586-022-05600-5. PubMed PMID:36697836 PubMed Central PMC9931578.
  12. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023;614 (7948):E38. doi: 10.1038/s41586-022-05597-x. PubMed PMID:36697835 PubMed Central PMC9931568.
  13. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Author Correction: Pan-cancer analysis of whole genomes. Nature. 2023;614 (7948):E39. doi: 10.1038/s41586-022-05598-w. PubMed PMID:36697834 PubMed Central PMC9931570.
  14. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023;614 (7948):E42. doi: 10.1038/s41586-022-05601-4. PubMed PMID:36697833 PubMed Central PMC9931577.
  15. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023;614 (7948):E40. doi: 10.1038/s41586-022-05599-9. PubMed PMID:36697832 PubMed Central PMC9931557.
  16. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Author Correction: Genomic basis for RNA alterations in cancer. Nature. 2023;614 (7948):E37. doi: 10.1038/s41586-022-05596-y. PubMed PMID:36697831 PubMed Central PMC9931574.
  17. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .

Search PubMed

  1. Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E et al.. Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022]. Eur Urol. 2023;83 (2):e60. doi: 10.1016/j.eururo.2022.11.018. PubMed PMID:36526492 .
  2. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2022;5 (1):1347. doi: 10.1038/s42003-022-03769-z. PubMed PMID:36482178 PubMed Central PMC9732278.
  3. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2022;13 (1):7567. doi: 10.1038/s41467-022-32336-7. PubMed PMID:36482170 PubMed Central PMC9731941.
  4. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2022;13 (1):7574. doi: 10.1038/s41467-022-32328-7. PubMed PMID:36481818 PubMed Central PMC9731961.
  5. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2022;13 (1):7571. doi: 10.1038/s41467-022-32343-8. PubMed PMID:36481739 PubMed Central PMC9732291.
  6. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Author Correction: Inferring structural variant cancer cell fraction. Nat Commun. 2022;13 (1):7568. doi: 10.1038/s41467-022-32338-5. PubMed PMID:36481724 PubMed Central PMC9732297.
  7. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2022;13 (1):7573. doi: 10.1038/s41467-022-32329-6. PubMed PMID:36481665 PubMed Central PMC9732335.
  8. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Author Correction: Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2022;13 (1):7570. doi: 10.1038/s41467-022-32342-9. PubMed PMID:36481658 PubMed Central PMC9731958.
  9. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2022;13 (1):7572. doi: 10.1038/s41467-022-32333-w. PubMed PMID:36481652 PubMed Central PMC9732340.
  10. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2022;13 (1):7569. doi: 10.1038/s41467-022-32339-4. PubMed PMID:36481612 PubMed Central PMC9731962.
  11. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2022;13 (1):7566. doi: 10.1038/s41467-022-32334-9. PubMed PMID:36481610 PubMed Central PMC9732045.
  12. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023;83 (3):246-258. doi: 10.1002/pros.24456. PubMed PMID:36325820 .
  13. Bernard, D, Martinez-Leal, JF, Rizzo, S, Martinez, D, Hudson, D, Visakorpi, T et al.. Retraction Note: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene. 2022;41 (45):4980. doi: 10.1038/s41388-022-02502-8. PubMed PMID:36253447 .
  14. Siltari, A, Lönnerbro, R, Pang, K, Shiranov, K, Asiimwe, A, Evans-Axelsson, S et al.. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2023;21 (2):316.e1-316.e11. doi: 10.1016/j.clgc.2022.09.006. PubMed PMID:36243664 .
  15. Kukkonen, K, Autio-Kimura, B, Rauhala, H, Kesseli, J, Nykter, M, Latonen, L et al.. Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen. Endocr Relat Cancer. 2022;29 (12):717-733. doi: 10.1530/ERC-22-0108. PubMed PMID:36219867 PubMed Central PMC9644224.
  16. Buhigas, C, Warren, AY, Leung, WK, Whitaker, HC, Luxton, HJ, Hawkins, S et al.. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022;21 (1):183. doi: 10.1186/s12943-022-01644-3. PubMed PMID:36131292 PubMed Central PMC9494848.
  17. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and prostate cancer survival in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2024;27 (1):73-80. doi: 10.1038/s41391-022-00597-4. PubMed PMID:36131010 PubMed Central PMC10876474.
  18. Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E et al.. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. Eur Urol. 2023;83 (3):212-221. doi: 10.1016/j.eururo.2022.07.018. PubMed PMID:36089529 .
  19. Peltomaa, AI, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers (Basel). 2022;14 (12):. doi: 10.3390/cancers14122920. PubMed PMID:35740586 PubMed Central PMC9221017.
  20. Salminen, JK, Mehtola, A, Talala, K, Taari, K, Mäkinen, J, Peltola, J et al.. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2022;127 (4):704-711. doi: 10.1038/s41416-022-01817-3. PubMed PMID:35505251 PubMed Central PMC9381528.
  21. Åkerla, J, Pesonen, JS, Pöyhönen, A, Koskimäki, J, Häkkinen, J, Huhtala, H et al.. Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. J Urol. 2022;207 (6):1285-1294. doi: 10.1097/JU.0000000000002450. PubMed PMID:35470712 .
  22. Scaravilli, M, Koivukoski, S, Gillen, A, Bouazza, A, Ruusuvuori, P, Visakorpi, T et al.. miR-32 promotes MYC-driven prostate cancer. Oncogenesis. 2022;11 (1):11. doi: 10.1038/s41389-022-00385-8. PubMed PMID:35228520 PubMed Central PMC8885642.
  23. Smith, MR, Hussain, M, Saad, F, Fizazi, K, Sternberg, CN, Crawford, ED et al.. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386 (12):1132-1142. doi: 10.1056/NEJMoa2119115. PubMed PMID:35179323 PubMed Central PMC9844551.
  24. Jeyapala, R, Kamdar, S, Olkhov-Mitsel, E, Zlotta, A, Fleshner, N, Visakorpi, T et al.. Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clin Genitourin Cancer. 2022;20 (3):e217-e226. doi: 10.1016/j.clgc.2022.01.003. PubMed PMID:35151601 .
  25. Ruusuvuori, P, Valkonen, M, Kartasalo, K, Valkonen, M, Visakorpi, T, Nykter, M et al.. Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment. Heliyon. 2022;8 (1):e08762. doi: 10.1016/j.heliyon.2022.e08762. PubMed PMID:35128089 PubMed Central PMC8800033.
  26. Eskelinen, T, Veitonmäki, T, Kotsar, A, Tammela, TLJ, Pöyhönen, A, Murtola, TJ et al.. Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 2022;33 (2):313-320. doi: 10.1007/s10552-021-01527-w. PubMed PMID:34921656 PubMed Central PMC8776666.
  27. Vettenranta, A, Murtola, TJ, Raitanen, J, Raittinen, P, Talala, K, Taari, K et al.. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. JAMA Oncol. 2022;8 (1):61-68. doi: 10.1001/jamaoncol.2021.5672. PubMed PMID:34817559 PubMed Central PMC8777566.
  28. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Sauna habits/bathing and changes in lower urinary tract symptoms – Tampere Ageing Male Urologic Study (TAMUS). Scand J Urol. 2022;56 (1):77-82. doi: 10.1080/21681805.2021.2002403. PubMed PMID:34783288 .

Search PubMed

Search PubMed

Search PubMed

  1. Eerola, SK, Santio, NM, Rinne, S, Kouvonen, P, Corthals, GL, Scaravilli, M et al.. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion. Cell Commun Signal. 2019;17 (1):148. doi: 10.1186/s12964-019-0463-y. PubMed PMID:31730483 PubMed Central PMC6858710.
  2. Booth, N, Rissanen, P, Tammela, TLJ, Kujala, P, Stenman, UH, Taari, K et al.. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS One. 2019;14 (11):e0224479. doi: 10.1371/journal.pone.0224479. PubMed PMID:31689326 PubMed Central PMC6830755.
  3. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .
  4. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
  5. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. Cancer Causes Control. 2019;30 (8):877-888. doi: 10.1007/s10552-019-01195-x. PubMed PMID:31209595 .
  6. Carlsson, SV, Månsson, M, Moss, S, Kwiatkowski, M, Recker, F, Tammela, TLJ et al.. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. Eur Urol. 2019;75 (6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. PubMed PMID:30928162 PubMed Central PMC7526685.
  7. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V et al.. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76 (1):43-51. doi: 10.1016/j.eururo.2019.02.009. PubMed PMID:30824296 PubMed Central PMC7513694.
  8. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  9. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer Prostatic Dis. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  10. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  11. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
  12. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  13. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. J Urol. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
  14. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res. 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  15. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  16. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.

Search PubMed

Search PubMed